伊布替尼联合CXCR4拮抗剂ulocuplumab治疗CXCR4突变华氏巨球蛋白血症的1期研究
MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target CXCR4Mut in WM.…
要点
- 伊布替尼联合ulocuplumab在CXCR4突变华氏巨球蛋白血症中可行,主要缓解率100%。
- 中位至轻微缓解0.9个月,至主要缓解1.2个月,2年无进展生存率估计90%。
- 常见≥2级不良事件包括可逆性血小板减少、皮疹和皮肤感染。
核心结论
- 伊布替尼联合CXCR4拮抗剂ulocuplumab在CXCR4突变华氏巨球蛋白血症中可行,支持进一步开发CXCR4拮抗剂。
研究设计与样本
- 1期试验,采用3+3剂量递增设计,伊布替尼420 mg/d从第1周期开始持续至不耐受或进展,ulocuplumab第1至6周期给药,每周期4周。
主要发现
- 最佳缓解时,中位血清免疫球蛋白M从5574降至1114 mg/dL。
- 骨髓疾病从65%降至10%,血红蛋白从10.1升至14.2 g/dL(P < .001)。
- 主要缓解率和VGPR率分别为100%和33%,VGPR在较低ulocuplumab剂量队列中观察到。
- 中位至轻微缓解和主要缓解时间分别为0.9个月和1.2个月。
- 中位随访22.4个月,估计2年无进展生存率为90%。
关键数值与推荐
- 主要缓解率100%,VGPR率33%。
- 中位血清免疫球蛋白M从5574降至1114 mg/dL,骨髓疾病从65%降至10%,血红蛋白从10.1升至14.2 g/dL(P < .001)。
- 中位至轻微缓解0.9个月,至主要缓解1.2个月。
- 中位随访22.4个月,估计2年无进展生存率90%。
临床怎么用
- 对于CXCR4突变华氏巨球蛋白血症,伊布替尼联合CXCR4拮抗剂ulocuplumab显示出可行性和高缓解率。
- 治疗期间需监测可逆性血小板减少、皮疹和皮肤感染等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target CXCR4Mut in WM. Ibrutinib was initiated at 420 mg/d with cycle 1 and continued until intolerance or progression; ulocuplumab was given cycles 1 to 6, with a 3 + 3 dose-escalation design. Each cycle was 4 weeks. Thirteen symptomatic patients, of whom 9 were treatment-naive patients were enrolled. Twelve were evaluable for response. At best response, their median serum immunoglobulin M declined from 5574 to 1114 mg/dL; bone marrow disease decreased from 65% to 10%, and hemoglobin increased from 10.1 to 14.2 g/dL (P < .001). The major and VGPR response rates were 100% and 33%, respectively, with VGPRs observed at lower ulocuplumab dose cohorts. Median times to minor and major responses were 0.9 and 1.2 months, respectively. With a median follow-up of 22.4 months, the estimated 2-year progression-free survival was 90%. The most frequent recurring grade ≥2 adverse events included reversible thrombocytopenia, rash, and skin infections. Ulocuplumab dose-escalation did not impact adverse events. The study demonstrates the feasibility of combining a CXCR4-antagonist with ibrutinib and provides support for the development of CXCR4-antagonists for CXCR4Mut WM. This trial was registered at www.clinicaltrials.gov as #NCT03225716.
引用
- Treon SP, Meid K, Hunter ZR, et al. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. Blood. 2021. PMID: 34289017. doi:10.1182/blood.2021012953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。